Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene STK11
Variant F298L
Impact List missense
Protein Effect unknown
Gene Variant Descriptions STK11 F298L lies within the protein kinase domain of the Stk11 protein (UniProt.org). F298L has been identified in the scientific literature (PMID: 27615706), but has not been biochemically characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, May 2024).
Associated Drug Resistance
Category Variants Paths

STK11 mutant STK11 F298L

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_000455.5
gDNA chr19:g.1221978T>C
cDNA c.892T>C
Protein p.F298L
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
XM_005259618.3 chr19:g.1221978T>C c.892T>C p.F298L RefSeq GRCh38/hg38
XM_005259617.3 chr19:g.1221978T>C c.892T>C p.F298L RefSeq GRCh38/hg38
XM_005259617 chr19:g.1221978T>C c.892T>C p.F298L RefSeq GRCh38/hg38
NM_000455 chr19:g.1221978T>C c.892T>C p.F298L RefSeq GRCh38/hg38
XM_005259618 chr19:g.1221978T>C c.892T>C p.F298L RefSeq GRCh38/hg38
NM_000455.4 chr19:g.1221978T>C c.892T>C p.F298L RefSeq GRCh38/hg38
NM_001407255.1 chr19:g.1221978T>C c.892T>C p.F298L RefSeq GRCh38/hg38
NM_000455.5 chr19:g.1221978T>C c.892T>C p.F298L RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
STK11 mutant breast cancer not applicable N/A Guideline Risk Factor Germline STK11 mutations are associated with increased risk of developing breast cancer (NCCN.org). detail...
STK11 mutant small intestine adenocarcinoma not applicable N/A Guideline Risk Factor Peutz-Jeghers syndrome often results from mutations in the STK11 gene, and is associated with increased risk of developing small bowel adenocarcinoma (NCCN.org). detail...
STK11 mutant stomach cancer not applicable N/A Guideline Risk Factor Germline mutations in STK11 result in Peutz Jeghers syndrome, which is associated with increased risk of developing gastric cancer (NCCN.org). detail...
STK11 mutant lung non-small cell carcinoma decreased response unspecified PD-L1 antibody Clinical Study - Cohort Actionable In a clinical study, mutant STK11 correlated with a worse outcome with immune checkpoint inhibitor treatment compared to wild-type STK11 in non-small cell lung cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #1138PD). detail...
STK11 mutant pancreatic cancer not applicable N/A Guideline Risk Factor Germline mutations in STK11 result in Peutz Jeghers syndrome, which is associated with increased risk of developing pancreatic cancer (NCCN.org). detail...
STK11 mutant lung non-small cell carcinoma sensitive Gedatolisib Preclinical Actionable In a preclinical study, Gedatolisib (PF-05212384) inhibited growth of human non-small cell lung carcinoma cells harboring an STK11 mutation in culture (PMID: 21325073). 21325073
STK11 mutant lung adenocarcinoma not predictive unspecified PD-L1 antibody Clinical Study - Cohort Actionable In a clinical study, lung adenocarcinoma patients harboring an STK11 mutation demonstrated a shorter progression free survival compared to patients with wild-type STK11 when treated with an unspecified PD-L1 antibody treatment, but when compared to other treatments, all were associated with shorter progression free survival (PMID: 32312757). 32312757
STK11 mutant lung non-small cell carcinoma decreased response unspecified PD-1 antibody Clinical Study - Cohort Actionable In a clinical study, mutant STK11 correlated with a worse outcome with immune checkpoint inhibitor treatment compared to wild-type STK11 in non-small cell lung cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #1138PD). detail...
STK11 mutant lung adenocarcinoma not predictive unspecified PD-1 antibody Clinical Study - Cohort Actionable In a clinical study, lung adenocarcinoma patients harboring an STK11 mutation demonstrated a shorter progression free survival compared to patients with wild-type STK11 when treated with an unspecified PD-1 antibody treatment, but when compared to other treatments, all were associated with shorter progression free survival (PMID: 32312757). 32312757
STK11 mutant lung non-squamous non-small cell carcinoma predicted - sensitive Camrelizumab + Rivoceranib Phase Ib/II Emerging In a Phase Ib/II trial, non-squamous NSCLC patients harboring STK11 and/or KEAP1 mutations (n=14) demonstrated an improved 12-month survival rate (85.1% vs 53.1%; p=0.01), and a trend towards improved objective response rate (42.9% vs 28.1%; p=0.33), disease control rate (92.9% vs 65.6%, p=0.053), and median progression-free survival (9.4 vs 5.3 months; p=0.64) compared to wild-type STK11/KEAP1 patients (n=32) treated with Camrelizumab (SHR-1210) plus Rivoceranib (apatinib) (PMID: 33323401; NCT03083041). 33323401
STK11 mutant lung adenocarcinoma not applicable N/A Clinical Study Emerging In clinical studies, STK11 mutations were associated with an inferior prognosis in patients with lung adenocarcinoma (PMID: 32312757, PMID: 32413741). 32413741 32312757